Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Hemab ApS
BioCentury | Feb 22, 2023
Regulation
Feb. 21 Quick Takes: Crossovers back Hemab in $135M series B
Plus: FDA reviewing Onpattro for larger ATTR indication; EU gets first hemophilia B gene therapy; and updates from Merck, Pfizer and more
BioCentury | Jan 19, 2022
Management Tracks
Interim no more: Zhang assumes Overland’s CEO post; Maraganore, Ho join as advisers
Plus: Merck KGaA strategy, R&D execs; and updates from CureVac, Exo, Krystal and more
BioCentury | Jan 6, 2022
Management Tracks
RTW levels up by adding Maraganore, promoting company creator Fong
In latest ‘retirement’ post, John Maraganore joins the team of an early Alnylam investor to help guide the firm’s next-gen portfolio companies
BioCentury | Sep 22, 2021
Management Tracks
CEO Anido out at Aerie after Phase II data
Plus: Sage, Gossamer Bio, Nimbus, Inventiva, Selecta and more
BioCentury | Jul 22, 2021
Emerging Company Profile
Hemab: $55M series A for Novo vets developing bispecific for rare bleeding disorders
Emerging Company Profile: Hemab advances program Novo had deprioritized
BioCentury | Jul 9, 2021
Management Tracks
Borio joins CEPI as SAB member; plus Aeglea, Codiak, Nordic Nanovector, BioShin and more
Luciana Borio, the senior fellow for global health at the Council on Foreign Relations, became a member of the scientific advisory board at Coalition for Epidemic Preparedness Innovations (CEPI).
BioCentury | Dec 15, 2020
Finance
Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more
Vida leads Locanabio’s $100M B roundLocanabio Inc. raised $100 million in a series B financing led by Vida Ventures, with participation from new investors RA Capital, Invus, Acuta Capital
Items per page:
1 - 7 of 7